v3.26.1
Operating Segments - Segment Revenues and Profit (Loss) (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Operating Segments    
Number of operating segments | segment 2  
Number of reportable segments | segment 2  
Research and development $ 1,782,300 $ 1,941,680
General and administrative 1,102,538 1,084,828
Adjusted loss from operations (2,884,838) (3,026,508)
Share-based compensation 121,208 63,599
Loss from operations (2,884,838) (3,026,508)
Other income, net 59,873 75,240
Net loss before income taxes (2,824,965) (2,951,268)
Reportable segments    
Operating Segments    
Loss from operations (1,692,886) (1,836,690)
Reportable segments | Specialized BioTherapeutics    
Operating Segments    
Research and development 1,645,097 1,750,602
Adjusted loss from operations (1,645,097) (1,750,602)
Share-based compensation 44,470 26,488
Depreciation and amortization 659 364
Loss from operations (1,690,226) (1,777,454)
Net loss before income taxes (1,690,226) (1,777,454)
Reportable segments | Public Health Solutions    
Operating Segments    
Research and development 2,550 58,335
Adjusted loss from operations (2,550) (58,335)
Share-based compensation   840
Depreciation and amortization 110 61
Loss from operations (2,660) (59,236)
Net loss before income taxes (2,660) (59,236)
Corporate    
Operating Segments    
Research and development 89,414 104,990
General and administrative 1,025,471 1,048,374
Adjusted loss from operations (1,114,885) (1,153,364)
Share-based compensation 76,738 36,271
Depreciation and amortization 329 183
Loss from operations (1,191,952) (1,189,818)
Other income, net 59,873 75,240
Net loss before income taxes (1,132,079) (1,114,578)
Adjustments    
Operating Segments    
Research and development 45,239 27,753
General and administrative 77,067 36,454
Adjusted loss from operations (122,306) (64,207)
Share-based compensation (121,208) (63,599)
Depreciation and amortization $ (1,098) $ (608)